Clinical trials: Prostate Cancer, Castration Resistant
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
This phase II trial tests how well pertuzumab, trastuzumab, hyaluronidase-zzxf and enzalutamide works in treating patients with castration-resistant prostate cancer that has spread from where it first started to other places in…
- Trial name
- NCT05730712
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Prostate Cancer
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel…
- Trial name
- CAPItello280 (NCT05348577)
- Testing
- capivasertib, docetaxel
- Where
- 217 sites in United States, Australia and 20 more
- Volunteers
- 1,035 people
- Sponsor
- AstraZeneca
Cancer of the Prostate, Neoplasms, Prostate
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
This study will be conducted in three parts. Part A is a dose-escalation study to determine two safe and tolerable doses of ASN001 for men with metastatic castration resistant prostate cancer.
- Conditions
- Cancer of the Prostate, Neoplasms, Prostate, Prostate Cancer, Prostatic Cancer
- Trial name
- NCT02349139
- Testing
- ASN001: Escalating dose Part A
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- Asana BioSciences
Neoplasms, Prostatic Neoplasms, Castration-Resistant
HTL0039732 in Participants With Advanced Solid Tumours
The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with…
- Conditions
- Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms
- Trial name
- NCT05944237
- Testing
- HTL0039732 Capsules, HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion
- Where
- 6 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cancer Research UK
Hormone Refractory Prostate Cancer
Molecular Phenotype Changes and Personalized Treatment for CRPC
To explore the molecular phenotypic changes and personalized treatment in castration-resistant prostate cancer.
- Trial name
- NCT02208583
- Testing
- Docetaxel & Prednisone, DP & Targeted drugs, cisplatin & Etoposide
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Prostate Cancer
Japanese Research for Patients With Non-metastatic Castration Resistant Prostate Cancer - Enzalutamide
The purpose of this study is to investigate the efficacy and safety of enzalutamide in patients with non-metastatic castration resistant prostate cancer. The total duration of the study will be 5 years.
- Trial name
- JCASTRE-Zero (NCT02588001)
- Testing
- Enzalutamide
- Where
- 4 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Metastatic Castration-resistant Prostate Cancer
Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer
Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC) Open-label, randomized phase II trial in…
- Trial name
- RAPSON (NCT03230734)
- Testing
- Radium-223, Docetaxel
- Where
- 15 sites in Italy
- Volunteers
- 70 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
- Trial name
- P300 (NCT06785636)
- Testing
- Pocenbrodib, Pocenbrodib and Darolutamide
- Where
- 19 sites in United States
- Volunteers
- 120 people
- Sponsor
- Pathos AI, Inc.
Prostate Cancer
A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the serum testosterone levels in patients with Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate as Compared to Abiraterone Acetate
- Trial name
- STAAR (NCT02737332)
- Testing
- Zytiga® (Abiraterone Acetate), SoluMatrix™ (Abiraterone Acetate)
- Where
- 17 sites in United States
- Volunteers
- 53 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
This example Phase 1 study is designed to evaluate the safety, tolerability, feasibility, and preliminary anti-tumor activity of ETB-DualNK-01, an allogeneic dual-target PSMA/PSCA CAR-NK cell therapy, in adults with metastatic…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma, PSCA-positive Prostate Cancer, PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
- Trial name
- DUAL-NK-PC (NCT07641049)
- Testing
- ETB-DualNK-01, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Castration-Resistant Prostatic Cancer, Metastatic Disease
Safety and Targeting of Anti-hk2 Antibody in mCRPC
This is an imaging trial, to develop h11B6 as a therapeutic radiopharmaceutical for men with mCRPC. This imaging study will be conducted to confirm the safety and estimate the mass amount of antibody h11B6, and confirm in vivo…
- Trial name
- NCT04116164
- Testing
- 111In-DOTA-h11B6
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- SpectronRX
Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC)
JUR-003 in Adult Patients With Metastatic Prostate Cancer
JUR-003-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of JUR-003 in patients with prostate cancer.
- Conditions
- Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC), Metastatic Hormone Sensitive Prostate Cancer
- Trial name
- NCT07824349
- Testing
- JUR-003
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- Juri Biosciences, Inc.
Prostate Cancer
A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy
This research is being done to test an investigational drug, called itraconazole, in the treatment of prostate cancer. Itraconazole is approved by the Food and Drug Administration (FDA) for the treatment of various fungal…
- Trial name
- NCT00887458
- Testing
- Itraconazole 200 mg, Itraconazole 300mg
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Johns Hopkins University
Prostate Cancer, Castrate Resistant Prostate Cancer
Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer
This is an open-label, multicenter, interventional study in racially self-identified black or ethnically self-identified hispanic and racially self-identified white or native American participants with metastatic…
- Conditions
- Prostate Cancer, Castrate Resistant Prostate Cancer, Homologous Recombination Deficiency
- Trial name
- REPRESENTATION (NCT06527690)
- Testing
- Niraparib/Abirate rone acetate fixed-dose combination, Prednisone
- Sponsor
- Latin American Cooperative Oncology Group
Metastatic Castration Resistant Prostate Cancer
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.
- Trial name
- TRITON2 (NCT02952534)
- Testing
- Rucaparib
- Where
- 149 sites in United States, Australia and 10 more
- Volunteers
- 277 people
- Sponsor
- pharmaand GmbH
Prostate Cancer, Metabolic Syndrome
MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism
The purpose of this study is to investigate if androgen deprivation therapy in men with prostate cancer increases hepatic fat content and changes visceral/subcutaneous fat distribution.
- Conditions
- Prostate Cancer, Metabolic Syndrome, Hypogonadism, Fatty Liver
- Trial name
- NCT02102646
- Testing
- Triptorelin, Orchiectomy
- Where
- Denmark
- Volunteers
- 31 people
- Sponsor
- Herlev Hospital
Metastatic Castration Resistant Prostate Cancer
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment…
- Trial name
- TRITON3 (NCT02975934)
- Testing
- Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel
- Where
- 150 sites in United States, Australia and 10 more
- Volunteers
- 405 people
- Sponsor
- pharmaand GmbH
Prostate Cancer
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
The purpose of this study is to determine if asymptomatic or minimally symptomatic patients with metastatic prostate cancer who have not received chemotherapy live longer when treated with ipilimumab than those treated with a…
- Trial name
- NCT01057810
- Testing
- Ipilimumab
- Where
- 134 sites in United States, Argentina and 22 more
- Volunteers
- 837 people
- Sponsor
- Bristol-Myers Squibb
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Prostate Cancer
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Protocol G200712 is a Phase II, exploratory study to assess the effects of GTx-758 on serum prostate specific antigen (PSA) response ans serum PSA progression in men with Metastatic Castration Resistant Prostate Cancer (mCRPC) on…
- Trial name
- NCT01615120
- Testing
- GTx-758 125 mg, GTx-758 250 mg
- Where
- 26 sites in United States
- Volunteers
- 77 people
- Sponsor
- GTx
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.